$GPGI

GPGI, Inc. (GPGI): Results of Operations and Financial Condition

GPGI, Inc. (GPGI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gpgi_2q26earningspresent.htm EX-99.2 gpgi_2q26earningspresent Second Quarter 2026 Earnings Presentation August 6, 2026 TM Disclaimer 2 Forward-Looking Statements This presentation, and other statements that GPGI, Inc. (“GPGI,” “we,” “us” or the “Company”) may make in co

Original reporting
Published Aug 6, 2026, 11:03 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$GPGI
Neutral
low confidence
Mentioned
$GPGI
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GPGINeutralMed
01

Why it matters

Traders should treat this as a guidance confirmation event for 2026, with emphasis on whether the company’s platform progress at CompoSecure and headwinds at Husky are consistent with the reiterated outlook.

02

Market read

This is a same-day earnings/guidance disclosure that can move the stock if the full presentation’s numbers and guidance ranges differ from expectations.

03

What to watch

Investors may discount the headline EBITDA improvement if the presentation’s pro forma assumptions (including the Husky transaction timing) materially drive comparability.

Relevance 7/10Novelty 5/10Timing: today’s SEC 8-K earnings presentation (pre-market/filing day)

Background

The filing is an SEC Form 8-K for Item 2.02, attaching GPGI’s 2Q26 earnings presentation with non-GAAP/pro forma methodology and forward-looking guidance language.

Company-level read

Ticker impact

$GPGINeutralLow confidence
Context

GPGI filed an 8-K with its 2Q26 earnings presentation, reiterating full-year 2026 guidance and reporting Pro Forma Adjusted EBITDA up 7% at the midpoint.

Expected impact

Moderate volatility possible around guidance credibility, but direction depends on any missing numeric details not shown in the scrape.

Evidence & confidence

The scrape includes only partial highlights and forward-looking/guidance framing, without the full set of financial figures or guidance ranges.

Market effects

Limited from the provided text; the filing is company-specific with no broader sector regulatory or macro catalyst disclosed.

None stated in the provided excerpt beyond generic global headwind language.

None stated beyond general input price and geopolitical risk disclaimers.

Counterpoint

If the market is focused on GAAP-to-non-GAAP adjustments or the spin-off accounting shift, the reiterated guidance may be viewed as less transparent than investors expect.

Key entities

  • GPGI, Inc.

    Subject of the 8-K and 2Q26 earnings presentation, reiterating full-year 2026 guidance and highlighting pro forma EBITDA growth.

Related articles

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.

$GXOMed

GXO Logistics Q2 Earnings Call Highlights

GXO Logistics reported Q2 results and said it secured over $1 billion in expected incremental new-business revenue for 2026 and about $353 million for 2027. Management cited a $2.7 billion sales pipeline after quarter end. Operating cash flow was $76 million, free cash flow positive $12 million, cash $769 million, and net leverage 2.6x. GXO plans to target EBIT margins above 6% and deploy AI across ~50 sites in 2026.

$GRNDMed

Grindr Q2 Earnings Call Highlights

Grindr (NYSE:GRND) said free users remain central to its strategy, while AI tools are boosting engineering productivity. Management estimated engineering output rose about 2.5x from July 2025 to April 2026 with similar headcount, supporting a 39% to 42% adjusted EBITDA margin outlook. EDGE AI premium tier rollout is planned for later in fall; operating expenses ex cost of revenue were $71M vs $53M.

$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.